Patents by Inventor David Coughlan

David Coughlan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12076304
    Abstract: The present disclosure relates to methods of treating or preventing hematologic disorders by administration of 15-HEPE or compositions thereof.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: September 3, 2024
    Assignee: Afimmune Limited
    Inventors: John Climax, Moayed Hamza, Markus Weissbach, David Coughlan
  • Publication number: 20240260727
    Abstract: Certain embodiments disclose a contact lens holder including a rim forming a lens receptacle for receiving a lens and a flange integrally formed with and extending from the rim, flange comprising at least one tab, wherein at least one of a posterior surface of the flange and a posterior surface of the at least one tab comprises micro-structuring.
    Type: Application
    Filed: February 5, 2024
    Publication date: August 8, 2024
    Inventors: James M. Scott, Patrick John Sadd, David Cook, Sebastian Merx, Joshua Coyne, Kevin Coughlan
  • Patent number: 12017986
    Abstract: The present disclosure provides 15-oxo-EPA and 15-oxo-DGLA, compositions comprising 15-oxo-EPA and/or 15-oxo-DGLA, and methods of treating and/or preventing fibrosis, skin disorders, inflammation, kidney disease or renal dysfunction in a subject in need thereof by administering 15-oxo-EPA and/or 15-oxo-DGLA.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: June 25, 2024
    Assignee: DS Biopharma Limited
    Inventors: Mehar Manku, John Climax, David Coughlan
  • Publication number: 20230106655
    Abstract: The present invention relates to the compositions comprising 15-HEPE and methods of treatment relating to same.
    Type: Application
    Filed: May 20, 2022
    Publication date: April 6, 2023
    Inventors: David Coughlan, John Climax
  • Patent number: 11478442
    Abstract: The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: October 25, 2022
    Inventors: Mehar Manku, John Climax, David Coughlan, James Dunne
  • Publication number: 20220324788
    Abstract: The present disclosure provides 15-oxo-EPA and 15-oxo-DGLA, compositions comprising 15-oxo-EPA and/or 15-oxo-DGLA, and methods of treating and/or preventing fibrosis, skin disorders, inflammation, kidney disease or renal dysfunction in a subject in need thereof by administering 15-oxo-EPA and/or 15-oxo-DGLA.
    Type: Application
    Filed: November 16, 2021
    Publication date: October 13, 2022
    Inventors: Mehar Manku, John Climax, David Coughlan
  • Publication number: 20220265593
    Abstract: The present disclosure relates to methods of treating or preventing hematologic disorders by administration of 15-HEPE or compositions thereof.
    Type: Application
    Filed: May 6, 2022
    Publication date: August 25, 2022
    Inventors: John Climax, Moayed Hamza, Markus Weissbach, David Coughlan
  • Publication number: 20220133669
    Abstract: Provided herein are pharmaceutical compositions comprising 15-HETrE and methods of using the same to treat a variety of conditions and disorders.
    Type: Application
    Filed: October 29, 2021
    Publication date: May 5, 2022
    Inventors: John Climax, David Coughlan, Bill Downes, Tien Nghiem, Markus Weissbach, Moayed Hamza
  • Publication number: 20210322354
    Abstract: The present disclosure provides orally and/or topically deliverable pharmaceutical compositions comprising DGLA or a derivative thereof and/or 15-HETrE or a derivative thereof and methods of using same to treat a variety of conditions, diseases, and disorders, including but not limited to inflammatory, fibrotic, and proliferative conditions, diseases, and disorders.
    Type: Application
    Filed: November 30, 2020
    Publication date: October 21, 2021
    Inventors: John Climax, David Coughlan, Markus Weissbach, Moayed Hamza
  • Publication number: 20210315851
    Abstract: The present disclosure relates to methods of treating or preventing hematologic disorders by administration of 15-HEPE or compositions thereof.
    Type: Application
    Filed: April 3, 2020
    Publication date: October 14, 2021
    Inventors: John Climax, Moayed Hamza, Markus Weissbach, David Coughlan
  • Publication number: 20210230094
    Abstract: The present disclosure provides 15-oxo-EPA and 15-oxo-DGLA, compositions comprising 15-oxo-EPA and/or 15-oxo-DGLA, and methods of treating and/or preventing fibrosis, skin disorders, inflammation, kidney disease or renal dysfunction in a subject in need thereof by administering 15-oxo-EPA and/or 15-oxo-DGLA.
    Type: Application
    Filed: January 13, 2020
    Publication date: July 29, 2021
    Inventors: Mehar Manku, John Climax, David Coughlan
  • Publication number: 20210085628
    Abstract: The present disclosure provides compositions comprising 15-HEPE and methods of using same for treating and/or preventing cancer and neurological diseases in a subject in need thereof.
    Type: Application
    Filed: June 5, 2020
    Publication date: March 25, 2021
    Inventors: John Climax, David Coughlan
  • Publication number: 20210085627
    Abstract: The present disclosure provides compositions comprising 18-HEPE, 12-HEPE, and/or a derivative thereof and methods of using same to treat a variety of diseases and disorders.
    Type: Application
    Filed: September 25, 2019
    Publication date: March 25, 2021
    Inventors: David Coughlan, Moayed Hamza
  • Patent number: 10849870
    Abstract: The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: December 1, 2020
    Inventors: Mehar Manku, John Climax, David Coughlan, James Dunne
  • Publication number: 20200360331
    Abstract: The present disclosure relates to methods of treating or preventing metabolic syndrome and/or cardiometabolic disease by administration of 15-HEPE, 15-HETrE, or compositions thereof.
    Type: Application
    Filed: July 19, 2019
    Publication date: November 19, 2020
    Inventors: John Climax, David Coughlan
  • Publication number: 20200323807
    Abstract: The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 15, 2020
    Inventors: Mehar Manku, John Climax, David Coughlan, James Dunne
  • Patent number: 10716773
    Abstract: The present disclosure provides compositions comprising 15-HEPE and methods of using same for treating and/or preventing cancer and neurological diseases in a subject in need thereof.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: July 21, 2020
    Assignee: Afimmune Limited
    Inventors: John Climax, David Coughlan
  • Publication number: 20200181064
    Abstract: The present disclosure provides pharmaceutically acceptable stable salt forms of 15-lipoxygenase products, such as 15-HETrE lysine salt, compositions comprising same and methods of making and using same.
    Type: Application
    Filed: December 5, 2019
    Publication date: June 11, 2020
    Inventors: Mehar Manku, David Coughlan, Bill Downes
  • Publication number: 20200069627
    Abstract: The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.
    Type: Application
    Filed: November 8, 2019
    Publication date: March 5, 2020
    Inventors: Mehar Manku, John Climax, David Coughlan, James Dunne
  • Patent number: 10570083
    Abstract: The present disclosure provides 15-oxo-EPA and 15-oxo-DGLA, compositions comprising 15-oxo-EPA and/or 15-oxo-DGLA, and methods of treating and/or preventing fibrosis, skin disorders, inflammation, kidney disease or renal dysfunction in a subject in need thereof by administering 15-oxo-EPA and/or 15-oxo-DGLA.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: February 25, 2020
    Assignee: DS Biopharma Limited
    Inventors: Mehar Manku, John Climax, David Coughlan